Device Congress. Track B: Reimbursement. How to Convince the Medical Director Your Product is Special

Size: px
Start display at page:

Download "Device Congress. Track B: Reimbursement. How to Convince the Medical Director Your Product is Special"

Transcription

1 Track B: Reimbursement How to Convince the Medical Director Your Product is Special Michael Becker, GM Global Reimbursement, GE Healthcare Michael Bihari, MD, Health Care Consultant March 29, 2007

2 Key Questions We Will Address Today What are the do s and don ts in convincing the payers medical directors that your product is worth covering and reimbursing? What are medical directors looking for? How do they make decisions? And what are some strategies one successful medical company uses? 2

3 Before We Start... What is your Reimbursement Strategy? Where does discussion w/medical Director fit in your overall reimbursement strategy? Medical Director is just one stakeholder Medical Director may influence coverage decisions... don t forget about coding & payment 3

4 GEHC Reimbursement Program

5 Reimbursement Objectives 1. Accelerate reimbursement for new products 2. Respond to customer needs for existing products 3. Develop & advocate public health policies favorable to GEHC products 5

6 Reimbursement Objective #1 Reduce cycle time from product launch to customer paid & patient access Existing Procedure Existing Coding/Coverage/Payment Regulatory Approval New Procedure New Code (15 mos. min) New Payment (1-2 yrs) Expanded Coverage (1-5 yrs) $ Customer Paid + Improved Health Outcomes 0-7 years 6

7 Creating Surround Sound With Key Stakeholders Technology Assessmt Coverage support for payers based on clinical evidence Consumers/Patients Advocate access to technology through favorable coverage & appropriate payment Professional Societies Code application & utilization guidance, coverage support, clinical guidelines Coverage CMS Priv Payers Legislature Coding AMA CMS Payment CMS Priv Payers Industry Organizations Coverage and payment support, industry PR and collaboration opportunities Lobbying Lobby for coverage, protect payment Providers Petition for code, advocate for coverage, payment, protect payment Manufacturers New product reimbursement strategy, work w/payers on coverage & payment Employers Advocate for access to technology that increases quality and lowers costs 7

8 We Will Be Successful, If We Can Create Positive, Ongoing Dialogue With Payers Objectives of Payer Focus Understand coverage & payment policy processes (decision makers, influencers, requirements, timing, communication) and where we can influence Gather payer input into product reimbursement strategies: clinical trial design, reimb. tactics to support coverage Collaborate with payers to accelerate coverage for new technology, where appropriate 8

9 We Will Be Successful, If We Can Create Positive, Ongoing Dialogue With Payers Objectives of Payer Focus Develop relationship w/ major payers for open communications when favorable/unfavorable policy changes made (coverage, payment, utilization) Gather payer input on product development how to meet their needs (VBM/P4P data, pricing transparency; reducing medical errors; linking claims data w/ pt. history; provider accreditation) Identify opportunities to collaborate on major health policy initiatives (IT initiatives, VBM/P4P, Quality) 9

10 Meeting With Medical Director Preparing for the meeting Inventory payer relationships Select target payers Research target payer policies/positions Assemble clinical value story (WIIFM) Assess existing evidence 10

11 Meeting With Medical Director Preparing for the meeting Assess provider & professional society support Prepare agenda & presentation Determine/secure meeting participants Modify Reimbursement Strategy accordingly Maintain dialogue with payer 11

12 Meeting With Medical Director Who should attend the meeting? Practicing physician Technical expert Clinical trials design expert Senior company representative Consultant / Facilitator No Sales & Marketing 12

13 Meeting With Medical Director Meeting Agenda Objectives what is your ask? Disease overview Procedure/technology overview Evidence review & clinical trial plans Specific questions for payer Next Steps 13

14 Do s Must be part of overall reimbursement strategy Be prepared Be clear & consistent Be careful what you ask for Treat Medical Director as Customer 14

15 Don ts Over commit Raise the evidence bar Blow smoke Overstate outcome of meeting to commercial teams 15

16 Medical Director Perspective

17 Medical Device Companies Capital Personnel - researchers & medical workers Disease expertise - knowledge of disease states from device development process Clinical expertise - insights & outcomes from clinical trials Influence - tools & techniques to influence patients & providers Devices - clinical therapy 17

18 Things You Need to Know About Your Target Health Plans Structure of plan local/regional/national impacts the message Who is at risk and for what capitation/p4p Radar screen diagnoses and # lives Key decision makers bottom up vs. top down Competitive environment Political environment Coverage/Tech Assessment Process 18

19 Coverage/Tech Assessment Process Clinical vs. Reimbursement Usually separate process with clinical decision made first, BUT may vary with plan In most plans, a medical director chairs clinical committee process As part of process most plans use outside assessment companies (BCBS, Hayes, ECRI) Criteria: - FDA approval of technology/device - Documentation of safety - Must be as efficacious as current treatment - Improves health outcomes - Independent scientific evidence 19

20 Coverage/tech Assessment Process What Kick-starts the Medical Director? Outside Requests Most often from network providers Consumer Groups Patients Manufacturers Health plan staff Large employer Squeaky Wheels Process Initiation Will benefit health plan members Technology related to high utilization service or disease Will significantly reduce other health care costs And, I need to know that it s important! 20

21 Things to Do: Appreciate the role of the medical director I m your customer! Take the time to provide me with evidence-based information and tools to help me make an appropriate decision Make sure what you say to me is consistent with what you say to physicians and consumers KNOW YOUR STUFF! 21

22 More Things to Do: GET TRAINED! It is important that you understand how health plans function Learn the roles of key staff and what keeps them up at night Excellent training companies are available that have had extensive experience in the pharma industry 22

23 What Not to Do: Don t nag me, I m busy. I do care but I m juggling multiple projects Don t waste my time KNOW YOUR STUFF! Don t do anything that is not consistent with industry standards and ethical and legal business practices. 23

24 How to Influence Me Appropriately Surround Sound increase the noise level - Key opinion leaders - Local influential physicians - Clinical practice guidelines - National society evidence-based protocols - Non-branded disease awareness: increase the size of the pie benefits all patients - Practicing physician awareness: publish, present, via specialty societies - Work with employers and employer groups 24

25 How to Influence Me Appropriately Develop a relationship with me based on trust and mutual respect Learn best ways to communicate with me Be dedicated to my organization: research and know my plan Get involved in plan initiatives Provide value-added services that benefit the plan, providers, patients - Measurement tools to assess performance of care and services in health plans - Disease management tools - Focus on appropriate outcomes such as quality, utilization, cost, and satisfaction 25

26 Partner with Me Early involvement in product development, launch, and promotion Algorithms to support appropriate use Educational pieces Phase 4 trials Joint promotion of preferred devices Collaborative initiatives with plans, providers & employers 26

The Fundamentals of Reimbursement

The Fundamentals of Reimbursement The Fundamentals of Reimbursement Understanding How Coverage, Coding, and Payment Impact a Medical Technology Kelli Hallas Executive Vice President of Reimbursement Emerson Consultants, Inc. OMTEC June

More information

Market Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement

Market Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement Market Access Strategy and Planning: Succeeding in the Age of -based Reimbursement Presented by: Michael J. Lacey, Senior Director, Strategic Consulting (Life Sciences) Date: March 01, 2017 Truven Health

More information

MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013

MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013 MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013 Presented by: Michael A. Sanchez, M.A., CCA Principal

More information

Pre Market Reimbursement Strategies for New Technologies

Pre Market Reimbursement Strategies for New Technologies Pre Market Reimbursement Strategies for New Technologies Marilyn Denegre-Rumbin, JD MBA Director Payer-Reimbursement Strategy Strategy & Business Development December 1, 2015 Early Strategy Integration

More information

The Impact of Future Healthcare Reform on MedTech Communications

The Impact of Future Healthcare Reform on MedTech Communications J. Robert Paulson President & CEO NxThera, Inc. The Impact of Future Healthcare Reform on MedTech Communications Perspectives From an Early-Stage Medical Device Company The Impact of Future Healthcare

More information

ASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? Drew Baker GO FROM HERE?

ASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? Drew Baker GO FROM HERE? ASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? An ISPOR Issue Panel by the Value Assessment of Medical Devices Working Group of the Medical Device and

More information

MedTech/BioTech Reimbursement: Getting Paid in the USA. MDCC Greater MSP September, 2016

MedTech/BioTech Reimbursement: Getting Paid in the USA. MDCC Greater MSP September, 2016 MedTech/BioTech Reimbursement: Getting Paid in the USA MDCC Greater MSP September, 2016 1 World Wide Market Access through Life Sciences International, Inc. Mpls/St. Paul Chicago Mexico Brussels London

More information

Pricing and Reimbursement Strategies for Diagnostics

Pricing and Reimbursement Strategies for Diagnostics For a clearer market perspective Pricing and Reimbursement Strategies for Diagnostics Overcoming reimbursement issues and navigating the regulatory environment Report Price Publication date 1995/ 2885/$3835

More information

Ace Left Brain Stimulation Device Strategy for Medicare Coverage and Payment

Ace Left Brain Stimulation Device Strategy for Medicare Coverage and Payment Ace Left Brain Stimulation Device Strategy for Medicare Coverage and Payment Michael J. Ruggiero King & Spalding LLP 202-661-7866 mruggiero@kslaw.com I. Preparation and Analysis Preparation and Analysis

More information

INSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS

INSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS COMMENTS 1310 G Street, N.W. Washington, D.C. 20005 202.626.4780 Fax 202.626.4833 Before the INSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS On How Insurers Make Determinations

More information

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks?

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Fifth Annual National Congress on Health Care Compliance Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks? Michael P. Swiatocha February 8, 2002 Agenda Introduction - The US Pharmaceutical

More information

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry Jeffrey A. Bourret, M.S., R.Ph., FASHP Senior Director, Managed Markets Healthcare Systems Marketing

More information

Problems with Current Health Plans

Problems with Current Health Plans Problems with Current Health Plans Poor Integration, Coordination and Collaboration - Current plans offer limited coordination between the health plan, Providers, and the Members, as well as limited mobile

More information

2018 Predictive Analytics in Healthcare Trend Forecast

2018 Predictive Analytics in Healthcare Trend Forecast 2018 Predictive Analytics in Healthcare Trend Forecast 60% of healthcare executives forecast that using predictive analytics will save their organization 15% or more over the next five years Among those

More information

Financial and Operational Benchmarking Trends & Techniques

Financial and Operational Benchmarking Trends & Techniques Financial and Operational Benchmarking Trends & Techniques Susan Petrie Chief Operating Officer October 31, 2018 1 Capital Link - Overview Launched in 1995, nonprofit, HRSA national cooperative agreement

More information

Leveraging Real-World Data and Analytics in the Device Industry. Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics

Leveraging Real-World Data and Analytics in the Device Industry. Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics Leveraging Real-World Data and Analytics in the Device Industry Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics Agenda 1. Overview 2. What is Real World Data (RWD)? 3. How is RWD Currently

More information

Investor Presentation. August 2007

Investor Presentation. August 2007 Investor Presentation August 2007 Forward-Looking Statement This presentation should be considered forward-looking and is subject to various risk factors and uncertainties. For more information on those

More information

Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process

Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process Barbara Grenell, Preferred Health Strategies Harvard Medical Congress Pre-Conference Symposia

More information

The Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices. Michael Sanchez, M.A., CCA Reimbursement Advisor

The Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices. Michael Sanchez, M.A., CCA Reimbursement Advisor The Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices Michael Sanchez, M.A., CCA Reimbursement Advisor Disclaimer The reimbursement information provided in this presentation

More information

Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]

Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P] January 25, 2019 Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-4180-P P.O. Box 8013 Baltimore, MD 21244-8013 Re: Modernizing

More information

Digital Health Reimbursement: Getting Paid in the USA

Digital Health Reimbursement: Getting Paid in the USA Digital Health Reimbursement: Getting Paid in the USA Prepared for 4 October 2017 Daniel A. Lace, MD, CPE, FAAPL 1 Reimbursement Strategies, LLC Edward Black President, CEO Daniel Lace, MD Chief Clinical

More information

Overview of Reimbursement Strategies for Novel Medical Technologies

Overview of Reimbursement Strategies for Novel Medical Technologies Overview of Reimbursement Strategies for Novel Medical Technologies Nov 9, 2016 Goals and Objectives Develop understanding of U.S. medical technology reimbursement landscape and provide information about

More information

Avalere Health 2015 Industry Outlook

Avalere Health 2015 Industry Outlook 2015 Industry Outlook 2 Introduction Industry Outlook 2015 Changes in healthcare financing, delivery, and organization are transforming the sector. Health plans and providers are revising their business

More information

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy Under the Preceptorship of Dr. Craig Stern Pro Pharma Pharmaceutical Consultants, Inc. September 11, 2015 S OBJECTIVES

More information

Coding and Payment for Genomic Sequencing Procedures (GSPs) and Existing Advanced Diagnostic Laboratory Tests (ADLTs)

Coding and Payment for Genomic Sequencing Procedures (GSPs) and Existing Advanced Diagnostic Laboratory Tests (ADLTs) Coding and Payment for Genomic Sequencing Procedures (GSPs) and Existing Advanced Diagnostic Laboratory Tests (ADLTs) Clinical Laboratory Fee Schedule Public Meeting July 16, 2015 Baltimore, MD Coalition

More information

OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017

OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017 OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017 Wedding Day Preparation The Big Moment is Here Mr. & Mrs. Anderson Today s Presentation Center

More information

Managing the risk and unpredictable costs of transplants

Managing the risk and unpredictable costs of transplants Managing the risk and unpredictable costs of transplants Executive summary While payers understand that transplants will be a part of their medical expense, they may be unprepared for the financial volatility

More information

P&T Committee and monograph preparation. Dr. Coreen Montagna, PharmD

P&T Committee and monograph preparation. Dr. Coreen Montagna, PharmD P&T Committee and monograph preparation Dr. Coreen Montagna, PharmD Managed Care Managed care is based on the same basic principle as a household budget. Money in the form of monthly premiums comes in,

More information

Coding and Reimbursement

Coding and Reimbursement Coding and Reimbursement IORT Reimbursement Kathy Francisco The Pinnacle Health Group, Inc., Pennsylvania The statements of the healthcare professional giving this presentation reflect only their personal

More information

Clinical Trials Corporate Medical Policy

Clinical Trials Corporate Medical Policy Clinical Trials Corporate Medical Policy File name: Clinical Trials File code: UM.GEN.02 Origination: 12/31/2013 Last Review: 03/2017 Next Review: 03/2018 Effective Date: 06/01/2017 Description This medical

More information

Provide sufficient incentive for providers to maximize health outcomes and value while reducing costs;

Provide sufficient incentive for providers to maximize health outcomes and value while reducing costs; March 27, 2017 Francis J. Crosson, MD Chair Medicare Payment Advisory Commission 425 I Street, N.W., Suite 701 Washington, DC 20001 By Electronic Delivery Dear Chairman Crosson: On behalf of the American

More information

HEALTH SPENDING AND REFORM IMPLEMENTATION OCTOBER 2011

HEALTH SPENDING AND REFORM IMPLEMENTATION OCTOBER 2011 The Commonwealth Fund/Modern care Opinion Leaders Survey HEALTH SPENDING AND REFORM IMPLEMENTATION OCTOBER 2011 Introduction The Commonwealth Fund Opinion Leaders (HCOL) Survey was conducted by Harris

More information

Physical Therapy Facility Application

Physical Therapy Facility Application Physical Therapy Facility Application 1. Name and Mailing Address of Facility: 2. Agent: Contact Person: Phone: Fax: E-Mail: Website: 3. Tax ID: 4. License No. 5. Type of Coverage: Claims-Made Occurrence

More information

The Regulatory & Reimbursement Policy Landscape in Personalized Medicine: A (Payer s) Perspective

The Regulatory & Reimbursement Policy Landscape in Personalized Medicine: A (Payer s) Perspective The Regulatory & Reimbursement Policy Landscape in Personalized Medicine: A (Payer s) Perspective Girish Putcha, MD, PhD Director of Laboratory Science 12 December 2016 Disclaimer Any opinions expressed

More information

Compensation and Reimbursement

Compensation and Reimbursement 492 Pharmacy Management: Compensation and Reimbursement Positions Compensation and Reimbursement Revenue Cycle Compliance and Management (1710) To encourage pharmacists to serve as leaders in the development

More information

RISK SHARE AGREEMENTS

RISK SHARE AGREEMENTS THIRD PLENARY: Risk Sharing Agreements: Country Experiences, Challenges, and Lessons Learned Gergana Zlateva Pfizer Inc New York, NY, USA RISK SHARE AGREEMENTS Gergana Zlateva, PhD VP, Global Market Access

More information

PERFORMANCE AND TRAJECTORY

PERFORMANCE AND TRAJECTORY PERFORMANCE AND TRAJECTORY José (Joe) E. Almeida Chairman, President and CEO May 21, 2018 Safe Harbor Statement This presentation includes forward-looking statements concerning Baxter s financial results,

More information

REPORT OF THE COUNCIL ON MEDICAL SERVICE

REPORT OF THE COUNCIL ON MEDICAL SERVICE REPORT OF THE COUNCIL ON MEDICAL SERVICE CMS Report -I-0 Subject: Presented by: Referred to: Standardized Preauthorization Forms (Resolution -A-0) William E. Kobler, MD, Chair Reference Committee J (Kathleen

More information

Will Health Plans Kill the Laboratory Outreach Program?

Will Health Plans Kill the Laboratory Outreach Program? Will Health Plans Kill the Laboratory Outreach Program? Jane M. Hermansen MBA, MT(ASCP) Mayo Clinic Rochester, Minnesota Learning Objectives Describe emerging payer trends in today s healthcare environment

More information

GOVERNMENTAL AFFAIRS AND LEGAL MATTERS (A)

GOVERNMENTAL AFFAIRS AND LEGAL MATTERS (A) GOVERNMENTAL AFFAIRS AND LEGAL MATTERS (A) 50 Elimination of the Medicare Face to Face Reimbursement Introduced by the MSSNY Long-Term Care Subcommittee RESOLVED, that the Medical Society of the State

More information

Table of Contents. Summary of Senator John McCain s Health Care Platform Summary of Senator Barack Obama s Health Care Platform.

Table of Contents. Summary of Senator John McCain s Health Care Platform Summary of Senator Barack Obama s Health Care Platform. Table of Contents Summary of Senator John McCain s Health Care Platform.... 3 Summary of Senator Barack Obama s Health Care Platform.5 Comparison of 2008 Presidential Candidate Health Care Platforms....8

More information

KPIs & KEIs for Success

KPIs & KEIs for Success The Smart Manager Series (#3) KPIs & KEIs for Success Key principles & Survival Kit Tools October 2018 Smart Pharma Consulting Table of Contents 1. Introduction p. 2 2. Definitions p. 3 3. How to choose

More information

Putting the Pieces Together, a Review of the Benefits Investigation Process. Thomas Cohn, Asembia

Putting the Pieces Together, a Review of the Benefits Investigation Process. Thomas Cohn, Asembia Putting the Pieces Together, a Review of the Benefits Investigation Process Thomas Cohn, Asembia Introductions Thomas Cohn Chief Strategy Officer Asembia Tony Scheuth CEO and Managing Partner Point-of-Care

More information

Members: Abbott, Blue Cross Blue Shield of Massachusetts, Boston Scientific Corporation, Genentech, Inc., Medtronic, Inc., Premier, Inc.

Members: Abbott, Blue Cross Blue Shield of Massachusetts, Boston Scientific Corporation, Genentech, Inc., Medtronic, Inc., Premier, Inc. Stuart Altman, Ph.D., Chairman Robert Mechanic, M.B.A., Executive Director Informing innovative healthcare policy and practice ADVISORY BOARD Elizabeth Fowler, Ph.D., J.D. Johnson & Johnson Robert Galvin,

More information

Unlocking Growth in China Challenges and Opportunities. Yehong Zhang, PhD, MBA, Country Manager, IMS Greater China

Unlocking Growth in China Challenges and Opportunities. Yehong Zhang, PhD, MBA, Country Manager, IMS Greater China Unlocking Growth in China Challenges and Opportunities Yehong Zhang, PhD, MBA, Country Manager, IMS Greater China China: A Country of Great Change Nanjin Road 1980 Nanjin Road 2004 China: A Country of

More information

2008 Medicare Part D: Pharmacist's Survival Guide. Ronnie DePue, R.Ph., CGP

2008 Medicare Part D: Pharmacist's Survival Guide. Ronnie DePue, R.Ph., CGP 2008 Medicare Part D: Pharmacist's Survival Guide Ronnie DePue, R.Ph., CGP Objectives At the completion of this program, the participant will be able to: 1. Give an overview of the Medicare Prescription

More information

OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10,

OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10, OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10, 2017 Today s Presentation Center for Evidence-based Policy

More information

Teva Neuroscience and the National Multiple Sclerosis Society. Announce Release of Multiple Sclerosis Trend Report

Teva Neuroscience and the National Multiple Sclerosis Society. Announce Release of Multiple Sclerosis Trend Report Teva Neuroscience and the National Multiple Sclerosis Society Announce Release of Multiple Sclerosis Trend Report For Immediate Release November 26, 2007 For More Information Corrine Brewster (816) 508-5066

More information

The Physician-Owned Management Services Organization

The Physician-Owned Management Services Organization The Physician-Owned Management Services Organization By Joe Laden www.onemso.com/consulting A Management Services Organization (MSO) is a legal entity created to provide management and administrative services

More information

Health Plan Design Options August 23, 2012

Health Plan Design Options August 23, 2012 Health Plan Design Options August 23, 2012 Leslie Schneider Bill Danish 2012/2013 Employer Focus Managing costs while maintaining a benefits package that Supports organizational attraction and retention

More information

FAQ. 1. Will Single Payer cost my company more? Will there be a tax increase associated with Single Payer?

FAQ. 1. Will Single Payer cost my company more? Will there be a tax increase associated with Single Payer? FAQ 1. Will Single Payer cost my company more? Will there be a tax increase associated with Single Payer? Under Single Payer, employers will pay less because they will no longer provide commercial health

More information

Medical Device Regulatory, Reimbursement and Compliance Congress. Steve Ubl President and CEO AdvaMed

Medical Device Regulatory, Reimbursement and Compliance Congress. Steve Ubl President and CEO AdvaMed Medical Device Regulatory, Reimbursement and Compliance Congress Steve Ubl President and CEO AdvaMed March 28, 2007 Overview of Remarks About AdvaMed The Public Policy Environment AdvaMed s Priorities

More information

Financial and Operational Benchmarking

Financial and Operational Benchmarking Financial and Operational Benchmarking Jonathan Chapman Director of Community Health Center Advisory Services October 24, 2017 1 Capital Link - Overview Launched in 1995, nonprofit, HRSA national cooperative

More information

VALUE-BASED HEALTH AWARDS. Steve Priddy Executive Director, Value-Based Health

VALUE-BASED HEALTH AWARDS. Steve Priddy Executive Director, Value-Based Health VALUE-BASED HEALTH AWARDS Steve Priddy Executive Director, Value-Based Health Award Evaluation Criteria Program Design Culture of Health Provider & Stakeholder Relationships Process and Implementation

More information

PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches

PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches CBI s PAP 2017 Michelle Drozd, Deputy Vice President Policy & Research Department October 12, 2016 Agenda Recent trends

More information

Paul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support

Paul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support Administrative Policies and Procedures Manual VMC # 154.02 October 5, 2013 TO: FROM: SUBJECT: REFERENCES: SCVMC Employees Paul Lorenz, MBA Chief Executive Officer, SCVMC Continuing Medical Education (CME)

More information

Moderator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France

Moderator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France Comparing the challenges of comparative effectiveness Research in France, Italy and the Netherlands Current Situation and Perspectives Issue Panelists: F. Meyer, MD Advisor to President, France E. Xoxi,

More information

Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications

Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications AMCP Partnership Forum Designing Benefits and Payment Models for Innovative High Investment Medications Welcome Bri Palowitch, PharmD, BCGP Manager, Pharmacy Affairs Academy of Managed Care Pharmacy Disclaimer

More information

Sunshine and Aggregate Spend

Sunshine and Aggregate Spend Sunshine and Aggregate Spend Challenges and Leading Practices in Reporting Clinical Spend Sixth Annual Summit on Disclosure, Transparency and Aggregate Spend for Drug, Device and Biotech Companies February

More information

Building Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements

Building Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements Building Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements Kelly Willenberg, DBA, RN, CHRC, CHC, CCRP Kelly Willenberg & Associates Wendy S. Portier, MSN,

More information

Value-Based Pricing: The Good, The Bad, and The Ugly

Value-Based Pricing: The Good, The Bad, and The Ugly Value-Based Pricing: The Good, The Bad, and The Ugly Medical Device Regulatory, Reimbursement and Compliance Congress March 27, 2008 Randel E. Richner, BSN, MPH President, Founder Reform There is no problem,

More information

Challenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare

Challenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Challenges in High Dollar Drugs Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare Disclosure I have no relevant conflicts of interest to disclose Learning

More information

The Cost of Specialty Drugs: Payer Perspectives

The Cost of Specialty Drugs: Payer Perspectives ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports exploring important

More information

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT AN INNOVATIVE IDEA THAT CHANGED THE INDUSTRY In 2001, frustrated by the limitations and lack of transparency in the traditional pharmacy

More information

Society of Professors of Child and Adolescent Psychiatry. Michael Jellinek, M.D. May 9, 2013

Society of Professors of Child and Adolescent Psychiatry. Michael Jellinek, M.D. May 9, 2013 Society of Professors of Child and Adolescent Psychiatry Michael Jellinek, M.D. May 9, 2013 Health Care Reform: Drivers Extend Coverage (Social justice and efficiency) Cost (versus public acceptance, politics)

More information

THE $10,000 QUESTION: TACKLING THE COMPLEXITIES OF VALUE-BASED PHYSICIAN COMPENSATION

THE $10,000 QUESTION: TACKLING THE COMPLEXITIES OF VALUE-BASED PHYSICIAN COMPENSATION THE $10,000 QUESTION: TACKLING THE COMPLEXITIES OF VALUE-BASED PHYSICIAN COMPENSATION HFMA First Illinois Chapter August 12, 2014 Stu Schaff Manager, DGA Partners Agenda > Background & Context > Measures

More information

Introducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market

Introducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market Introducing Manulife DrugWatch Applying rigorous oversight to help ensure value for money in a dramatically changing drug market The drug market in Canada is changing rapidly and dramatically Many Canadians

More information

DPC as THE Advanced Alternative Payment Model

DPC as THE Advanced Alternative Payment Model DPC as THE Advanced Alternative Payment Model Brian Forrest, M.D., Access Healthcare Direct Submit your questions to: aafp3.cnf.io Activity Disclaimer The material presented here is being made available

More information

William Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles

William Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Provider Strategies Required to Succeed in a Consumer Driven Health Care Environment

Provider Strategies Required to Succeed in a Consumer Driven Health Care Environment Provider Strategies Required to Succeed in a Consumer Driven Health Care Environment John F.X. Lovett Consumer Driven Health Care What is consumer driven health care and how is it impacting on providers?

More information

PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES

PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES We at Sanofi work passionately, every day, to understand and solve health care needs of people across the world. We are dedicated to therapeutic

More information

BCBS National Clinical Innovation Acceleration Driving Smarter, Better Healthcare in Every Local Community

BCBS National Clinical Innovation Acceleration Driving Smarter, Better Healthcare in Every Local Community BCBS National Clinical Innovation Acceleration Driving Smarter, Better Healthcare in Every Local Community Session 37, March 6, 2018 Jody Voss Vice President, Development, Innovation and Group Purchasing

More information

PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING

PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING Sam Peasah PhD, MBA RPh. GA-AMCP-CCORE Winter Symposium March 3, 2018 Samuel Peasah, PhD, MBA, RPh Dr. Peasah

More information

BioMarin RareConnections Patient Enrollment Form for CLN2 Disease

BioMarin RareConnections Patient Enrollment Form for CLN2 Disease BioMarin RareConnections Patient Enrollment Form for CLN2 Disease Fax completed form to 1-888-863-3361 or email to support@biomarin-rareconnections.com Phone: 1-866-906-6100 Hours: M F 6 AM 5 PM (PST)

More information

Policies Targeting Administrative Simplification. Harry Reynolds Blue Cross Blue Shield of North Carolina

Policies Targeting Administrative Simplification. Harry Reynolds Blue Cross Blue Shield of North Carolina Policies Targeting Administrative Simplification September 10, 2009 Harry Reynolds Blue Cross Blue Shield of North Carolina Discussion Successful payer harmonization is occurring via industry-driven efforts

More information

Provider Manual Section 12.0 Outpatient Pharmacy Services

Provider Manual Section 12.0 Outpatient Pharmacy Services Provider Manual Section 12.0 Outpatient Pharmacy Services Table of Contents 12.1 Prescribing Outpatient Medications for Enrollees 12.2 Prescription Medications & Prior Authorization 12.3 Pharmacy Lock-In

More information

FINANCIAL CONFLICT OF INTEREST POLICY

FINANCIAL CONFLICT OF INTEREST POLICY FINANCIAL CONFLICT OF INTEREST POLICY Individuals who are appointed to serve on ABIM boards or committees are expected to have the American Board of Internal Medicine s (ABIM) mission as their primary

More information

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: Austria Year of Disclosure: 2018 for 2017

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca Pharma Poland Sp. z o.o. 0000117902 Postepu 14, 02-676 Warsaw Contents 1. Introduction...

More information

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018 AstraZeneca UK Limited Registered in England No 3674842 Registered Office, 2 Kingdom Street, London,

More information

HEALTHCARE: INTRODUCTION MAIN ISSUES IDENTIFIED BY THE COMMITTEE:

HEALTHCARE: INTRODUCTION MAIN ISSUES IDENTIFIED BY THE COMMITTEE: HEALTHCARE: The Future of Health in Estonia Multi-Sector Collaboration to Ensure Proper Business Climate, Healthy Workforce, and Attractiveness for Current & Future Investment INTRODUCTION The Estonian

More information

Understanding the Insurance Process

Understanding the Insurance Process Understanding the Insurance Process This summary provides an overview of the health insurance process. Health insurance falls into two major categories: commercial insurance and government insurance. Commercial

More information

Coverage Analysis and Research Billing Beyond SOC vs. Study Paid. March 14, 2014

Coverage Analysis and Research Billing Beyond SOC vs. Study Paid. March 14, 2014 Coverage Analysis and Research Billing Beyond SOC vs. Study Paid March 14, 2014 Overview Laws and regulations for billing for patients in clinical trials CMS s National Coverage Decision, Affordable Care

More information

Precision Medicine. A Health Economic perspective

Precision Medicine. A Health Economic perspective Precision Medicine. A Health Economic perspective Lieven Annemans Ghent University Lieven.annemans@ugent.be April 2018 1 Exponential technology exponential cost? http://medicalfuturist.com 2 Total public

More information

Questions and Answers. When should I use mail order pharmacy services? What is my co payment for drugs? What is my co payment for preferr

Questions and Answers. When should I use mail order pharmacy services? What is my co payment for drugs? What is my co payment for preferr WPDP/Moda Health Pharmacy Program Welcome to your new pharmacy program, offered through the Washington Prescription Drug Program (WPDP) and administered by Moda Health, formerly ODS Health. At Moda Health,

More information

Sutter Medical Network

Sutter Medical Network Sutter Medical Network Sutter Care Pattern Analyzer making the case for affordability Fifth National Pay for Performance Summit March 9, 2010 Michael van Duren, M.D., CMO Sutter Physician Services Colleen

More information

Pharmaceutical Market Trends

Pharmaceutical Market Trends Pharmaceutical Market Trends External research and findings Alex Jung 2017 Alex Jung Partner/Managing Director Direct: 312-879-2778 Mobile: 847-722-3482 Email: Alex.Jung@ey.com Office: 155 N Wacker Drive,

More information

PURPOSE: To establish minimum criteria for a supplier to considered for a HealthTrust contract.

PURPOSE: To establish minimum criteria for a supplier to considered for a HealthTrust contract. TITLE: Supplier Criteria PAGE: 1 of 3 EFFECTIVE DATE: May 2017 POLICY DESCRIPTION: Criteria for Consideration of Supplier in Contract Bid Process TYPE: National Agreements REFERENCE NUMBER: HT.010 SCOPE:

More information

Future Trends Affecting the Pharma, Biotech and Device Industries

Future Trends Affecting the Pharma, Biotech and Device Industries Future Trends Affecting the Pharma, Biotech and Device Industries Paul Banta Vice President, Law and Policy Epocrates, Inc. June 8, 2005 2005 Epocrates, Inc. All rights reserved. Slide 1 Schematic of the

More information

4/8/17. The Changing Nature of Physician Payment and Health Care Reform in The AMA A Unifying Voice for Physicians

4/8/17. The Changing Nature of Physician Payment and Health Care Reform in The AMA A Unifying Voice for Physicians The Changing Nature of Physician Payment and Health Care Reform in 2017 U of Mo Family Medicine Update April 7, 2017 David Barbe, MD MHA President-elect American Medical Association VP Regional Operations

More information

With those goals in mind, we wish to specifically address enteral nutrition.

With those goals in mind, we wish to specifically address enteral nutrition. March 24, 2014 Marilyn Tavenner Administrator, Centers for Medicare & Medicaid Services Baltimore, MD Re: CMS-1460-ANPRM We thank you for the opportunity to submit comments regarding the DEPARTMENT OF

More information

Q SPECIAL TOPIC REPORT: PROVIDER-OWNED HEALTH PLANS

Q SPECIAL TOPIC REPORT: PROVIDER-OWNED HEALTH PLANS THE ACADEMY LUMERIS STRATEGIC TRACKING SURVEY Q3 2018 SPECIAL TOPIC REPORT: PROVIDER-OWNED HEALTH PLANS SEPTEMBER 2018 PROVIDER-OWNED HEALTH PLANS INTRODUCTION As health systems increasingly participate

More information

Managing Specialty Pharmaceuticals: Balancing Access and Affordability

Managing Specialty Pharmaceuticals: Balancing Access and Affordability Managing Specialty Pharmaceuticals: Balancing Access and Affordability Commercial Health Plan Perspective The Health Industry Forum July 16, 2008 Presented by: Margaret M. (Peggy) Johnson, R.Ph. Vice President

More information

REPORT OF THE COUNCIL ON MEDICAL SERVICE. Prior Authorization Simplification and Standardization (Resolutions 705-A-15 and 712-A-15)

REPORT OF THE COUNCIL ON MEDICAL SERVICE. Prior Authorization Simplification and Standardization (Resolutions 705-A-15 and 712-A-15) REPORT OF THE COUNCIL ON MEDICAL SERVICE (A-) Prior Authorization Simplification and Standardization (Resolutions 0-A- and -A-) (Reference Committee G) EXECUTIVE SUMMARY At the Annual Meeting, the House

More information

Ensure Network Adequacy. May 23, 2017

Ensure Network Adequacy. May 23, 2017 May 23, 2017 The Honorable Orrin Hatch Chairman, Senate Finance Committee 219 Dirksen Senate Office Building Washington, DC 20510 Sent electronically to HealthReform@finance.senate.gov Dear Mr. Chairman,

More information

Milliman Healthcare Services

Milliman Healthcare Services Milliman Healthcare Services Milliman Introduction About Milliman Milliman is the leader in providing actuarial consulting services to the health industry. We also develop and maintain sophisticated healthcare

More information

Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study

Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study Presented by Bill O Brien, FSA, MAAA Consulting Actuary Milliman Houston, TX (832) 878-4078 Preconference I Agenda

More information

Health Care Reform in the United States

Health Care Reform in the United States Health Care Reform in the United States 4 Corners MGMA Conference April 2014 Karl Rebay, MBA, FHFMA Director, Health Care Consulting 1 The material appearing in this presentation is for informational purposes

More information

Redefining Health Care: Creating Value-Based Competition on Results

Redefining Health Care: Creating Value-Based Competition on Results Redefining Health Care: Creating Value-Based Competition on Results Presentation by Professor Michael E. Porter Harvard Business School New Models of Health Care Boston, MA April 12 th, 2005 This presentation

More information

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE Moderator Audrey Halvorson, Vice Chairperson, Health Practice Council Presenters Karen Bender, Member, Prescription Drug

More information